Design and Characterization of HER-2-Targeted Gold Nanoparticles for Enhanced X-radiation Treatment of Locally Advanced Breast Cancer

2010 ◽  
Vol 7 (6) ◽  
pp. 2194-2206 ◽  
Author(s):  
Niladri Chattopadhyay ◽  
Zhongli Cai ◽  
Jean-Philippe Pignol ◽  
Brian Keller ◽  
Eli Lechtman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gold Nanoparticles ◽  
Advanced Breast Cancer ◽  
Radiation Treatment ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Her 2

Characterization of HER1 (c-erbB1) Status in Locally Advanced Breast Cancer Using Fluorescence in situ Hybridization and Immunohistochemistry

Tumor Biology ◽  
2005 ◽  
Vol 26 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Cristina Corzo ◽  
Ignacio Tusquets ◽  
Marta Salido ◽  
Josep Maria Corominas ◽  
Meritxell Bellet ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridization ◽  
Advanced Breast Cancer ◽  
Fluorescence In Situ Hybridization ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast

scholarly journals The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Wei Zhang ◽  
Huan Tian ◽  
Shi-hong Yang
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Influencing Factors ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Clinical Staging ◽  
Increased Risk ◽  
Her 2

To provide reference data, we retrospectively investigated the effects of neoadjuvant chemotherapy (NAC) on 119 patients with HER-2+locally advanced breast cancer, treated from November 2010 to July 2016, with respect to influencing factors and survival. They were divided into the pathological complete response (pCR;n=15; 12.6%) and non-pCR (n=104; 87.4%) groups. We usedΧ2and logistic tests to the analyze effect and influencing factors. Survival rate was analyzed by the Kaplan-Meier method and Log-rank test. We lost 12 patients (including 1 pCR patient) and followed 107 patients, of whom 31 (all in the non-pCR group) had local recurrences or distant metastasis. The two groups significantly differed in 3-year disease-free survival (pCR group: 100%; non-pCR group: 59.0%;P=0.039); pCR was significantly affected by histological grade, PR status, Ki67 index, primary tumor size, clinical staging, and number of trastuzumab cycles. The model was tested, and the difference was statistically significant (Χ2 = 31.938,P=0.032). Patients with HER-2+locally advanced breast cancer with pCR responses to NAC have improved prognoses. Patients without pCR have increased risk for relapse. The use of a combination of NAC, such as trastuzumab and chemotherapy, and more cycles should be considered to increase the likelihood of pCR.

Sign in / Sign up

Export Citation Format

Share Document